SIMCERE PHARMA Secures Exclusive Rights to Promote Pemecitinib Gel

Stock News06-01

SIMCERE PHARMA (ASX: 02096) has announced the signing of an exclusive promotion services agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharma) for the Pemecitinib Gel.

Under the terms of the agreement, the group has secured exclusive rights to promote Pemecitinib Gel for all dermatological indications in mainland China, Hong Kong, and Macau.

The New Drug Application for the Pemecitinib Gel, targeting atopic dermatitis in adults and adolescents, has been accepted for review by the Center for Drug Evaluation of the National Medical Products Administration.

This collaboration is expected to strengthen the group's product portfolio in the autoimmune disease sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162893860?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 19:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162893860","market":"us","top_or_hot":-1,"title":"SIMCERE PHARMA Secures Exclusive Rights to Promote Pemecitinib Gel","media":"Stock News","content":"<p>SIMCERE PHARMA (ASX: 02096) has announced the signing of an exclusive promotion services agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharma) for the Pemecitinib Gel.<br><br>Under the terms of the agreement, the group has secured exclusive rights to promote Pemecitinib Gel for all dermatological indications in mainland China, Hong Kong, and Macau.<br><br>The New Drug Application for the Pemecitinib Gel, targeting atopic dermatitis in adults and adolescents, has been accepted for review by the Center for Drug Evaluation of the National Medical Products Administration.<br><br>This collaboration is expected to strengthen the group's product portfolio in the autoimmune disease sector.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIMCERE PHARMA Secures Exclusive Rights to Promote Pemecitinib Gel</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIMCERE PHARMA Secures Exclusive Rights to Promote Pemecitinib Gel\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-01 19:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIMCERE PHARMA (ASX: 02096) has announced the signing of an exclusive promotion services agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharma) for the Pemecitinib Gel.<br><br>Under the terms of the agreement, the group has secured exclusive rights to promote Pemecitinib Gel for all dermatological indications in mainland China, Hong Kong, and Macau.<br><br>The New Drug Application for the Pemecitinib Gel, targeting atopic dermatitis in adults and adolescents, has been accepted for review by the Center for Drug Evaluation of the National Medical Products Administration.<br><br>This collaboration is expected to strengthen the group's product portfolio in the autoimmune disease sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1162893860","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162893860","pubTimestamp":1780314017,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIMCERE PHARMA (ASX: 02096) has announced the signing of an exclusive promotion services agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharma) for the Pemecitinib Gel.Under...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1583":"高瓴概念","02096":"先声药业","BK1515":"抗疫概念","BK1161":"生物科技","BK1191":"制药","09939":"开拓药业-B","BK1574":"生物医药B类股"},"translate_title":"先声药业获得培美替尼凝胶独家推广权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02096":1,"09939":1},"content_text":"SIMCERE PHARMA (ASX: 02096) has announced the signing of an exclusive promotion services agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharma) for the Pemecitinib Gel.Under the terms of the agreement, the group has secured exclusive rights to promote Pemecitinib Gel for all dermatological indications in mainland China, Hong Kong, and Macau.The New Drug Application for the Pemecitinib Gel, targeting atopic dermatitis in adults and adolescents, has been accepted for review by the Center for Drug Evaluation of the National Medical Products Administration.This collaboration is expected to strengthen the group's product portfolio in the autoimmune disease sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162893860","isCrawlerRequest":true}